Ozempic, Wegovy, Mounjaro and alcohol: can they be taken together?

Short answer: Moderate alcohol consumption is not a problem for most people taking GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda, but the combination may exacerbate nausea and requires extra caution when used alongside treatment for diabetes or in cases of a previous history of pancreatitis.

Many people taking GLP-1 medicines find that they react differently to alcohol: reduced appetite, a feeling of fullness sooner, or, conversely, more side effects after just a few sips. This is no coincidence. GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda affect the same system that also controls how the body processes alcohol.

In this blog post, we discuss what is known about the combination of GLP-1 medicines and alcohol, and what you should bear in mind. We cover semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda) separately where relevant.

How do GLP-1 medicines affect your alcohol tolerance?

GLP-1 medicines slow down gastric emptying and enhance the feeling of fullness, and this effect is not limited to solid food. As the stomach empties more slowly, alcohol also reaches the small intestine – where it is absorbed into the bloodstream – at a slower rate. In theory, this delays the rate at which blood alcohol levels rise, but it can also mean that the alcohol remains in the stomach for longer and stimulates it before being absorbed.

When taken on an empty stomach, the effect is less predictable: some users report, on the contrary, that the alcohol seems to have a stronger effect. This mechanism, how GLP-1 medicines delay gastric emptying, underlies both the satiety effect and this altered response to alcohol. Controlled studies on the exact impact on the blood alcohol curve in humans are not yet available, so caution is advised.

Do GLP-1 medicines reduce the craving for alcohol?

There is a growing body of scientific research into whether GLP-1 agonists can reduce the craving for alcohol. A review of GLP-1 receptor agonists as a potential treatment for alcohol use disorder shows that these medicines affect the brain’s reward system, in the same way that they suppress the desire for food. This may occur via the dopamine pathway, which also plays a role in addictive behaviour. A recent systematic review of GLP-1 receptor agonists and alcohol dependence confirms that the initial results are promising, although the number of large clinical trials in humans remains limited.

Other studies on the role of GLP-1 in addiction susceptibility confirm that the effect extends beyond mere eating behaviour. Important: this is experimental research. GLP-1 medicines are not approved in the Netherlands as a treatment for alcohol dependence, and a reduced craving for alcohol must never be used to justify excessive alcohol consumption.

What are the risks of drinking alcohol whilst on GLP-1 treatment?

The main practical risk is that existing GLP-1 side effects may be exacerbated. Alcohol irritates the stomach lining, and as the medicine already slows down gastric emptying, this combination may worsen nausea, vomiting and other gastrointestinal symptoms. This is consistent with the common side effects of GLP-1 medicines, which already occur in some users even without alcohol. Furthermore, vomiting caused by alcohol, combined with reduced fluid intake, can lead to dehydration more quickly than in users who are not taking GLP-1 medicines.

For people with type 2 diabetes who, in addition to semaglutide or tirzepatide, also use insulin or a sulphonylurea, there is an increased risk of hypoglycaemia (low blood sugar): alcohol can inhibit the liver’s production of glucose, thereby enhancing the effect of blood-sugar-lowering medicines. In practice, this is a well-known factor to bear in mind for this group, even though the patient information leaflet does not explicitly mention alcohol as a risk factor.

What is the difference between the various medicines (Ozempic, Wegovy, Mounjaro, Saxenda)?

Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda) work on the same basic principle. They mimic a hormone produced naturally by the body that is released after meals. In this way, they help to keep blood sugar under control, curb appetite and ensure that the stomach empties more slowly. Tirzepatide also acts on an additional mechanism, which may enhance the effect on feelings of fullness and possibly also on the craving for alcohol. The practical difference lies mainly in how long they remain active in the body. Semaglutide and tirzepatide remain active for about a week, whilst liraglutide is active for only about half a day. Consequently, Saxenda is injected daily, whilst injections of the other two are required only once a week.

None of the official package leaflet texts in the Farmacotherapeutisch Kompas explicitly mention alcohol as an interaction or contraindication. The advice in this blog is therefore general precautionary advice based on the mechanism of action, not an official warning in the package leaflet. If you would like to see the options compared with one another, we have compiled a comparison of Ozempic, Wegovy, Mounjaro and Saxenda.

How much alcohol is permitted during GLP-1 treatment?

For most users who are not taking diabetes medication, there is no strict contraindication to moderate alcohol consumption. The general advice is to follow the Dutch guideline: no more than one glass per day, preferably with several alcohol-free days per week. According to the Farmacotherapeutisch Kompas, this advice on moderation applies in all cases to the general population, regardless of GLP-1 use.

There is no reason to assume that users of Wegovy, Mounjaro or Saxenda should systematically deviate from this. However, extra caution is advisable if you are already suffering from nausea, vomiting or bloating caused by the medication: alcohol may further exacerbate these symptoms.

When should you avoid alcohol whilst using GLP-1?

In cases of previous pancreatitis, it is particularly important to exercise caution with alcohol. Acute pancreatitis is a rare but serious potential side effect of semaglutide, tirzepatide and liraglutide, and a history of pancreatitis is considered a relative contraindication for all three. Regardless of this, alcohol is a recognised risk factor for pancreatitis, and when two independent risk factors coincide, the combined risk increases.

Even if you have existing liver problems, moderation with alcohol is recommended, given the shared metabolic pathway via the liver. If, in addition to semaglutide or tirzepatide, you are also using insulin or a sulphonylurea derivative to treat type 2 diabetes, it is advisable to limit your alcohol consumption and monitor your blood sugar levels more closely due to the increased risk of hypoglycaemia. If you are unsure whether your situation falls into any of these categories, you should consult your doctor or healthcare professional before drinking alcohol.

Alcohol and GLP-1 medicines: in moderation and with caution

Moderate alcohol consumption is not a problem for most people taking GLP-1 medicines, but it does require attention in terms of side effects and specific risk groups, such as people taking other diabetes medicines or with a history of pancreatitis. Goodweigh addresses this as standard during the intake process and throughout your coaching, so that you know what to look out for in your particular situation.